TULVEGIO RIVOCERANIB

Serial Number 98695795
688

Registration Progress

Application Filed
Aug 13, 2024
Under Examination
Sep 2, 2025
Approved for Publication
Jul 8, 2025
Published for Opposition
Jul 8, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Mar 02, 2026 64 days

Trademark Image

TULVEGIO RIVOCERANIB

Basic Information

Serial Number
98695795
Filing Date
August 13, 2024
Published for Opposition
July 8, 2025
Drawing Code
3

Status Summary

Current Status
Active
Status Code
688
Status Date
Sep 2, 2025
Application
Pending
Classes
005 042

Rights Holder

Elevar Therapeutics, Inc.

03
Address
2825 East Cottonwood Parkway, Suite 180
Salt Lake City, UT 84121

Ownership History

Elevar Therapeutics, Inc.

Original Applicant
03
Salt Lake City, UT

Elevar Therapeutics, Inc.

Owner at Publication
03
Salt Lake City, UT

Legal Representation

Attorney
Cynthia Johnson Walden

USPTO Deadlines

Next Deadline
64 days remaining
NOA E-Mailed - SOU Required
Due Date
March 02, 2026
Extension Available
Until September 02, 2026

Application History

15 events
Date Code Type Description Documents
Sep 2, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 8, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 8, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 2, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 2, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 8, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 8, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 8, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 5, 2025 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Mar 5, 2025 GPRA F PRIORITY ACTION E-MAILED Loading...
Mar 5, 2025 CPRA R PRIORITY ACTION WRITTEN Loading...
Feb 26, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 25, 2025 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Feb 25, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 13, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations and substances containing rivoceranib for the treatment of cancer
Class 042
Development of therapeutics in the nature of pharmaceutical preparations for the treatment of cancer containing rivoceranib

Additional Information

Design Mark
The mark consists of the wording "TULVEGIO RIVOCERANIB" in stylized font. A stylized human hand design appears to the left of the letter "T" in the word "TULVEGIO".
Color Claim
Color is not claimed as a feature of the mark.
Translation
The wording "TULVEGIO" has no meaning in a foreign language.

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"RIVOCERANIB"